William J. Catalona, MD; Stacy Loeb, MD; Misop Han, MD
Catalona WJ, Loeb S, Han M. Viewpoint: Expanding Prostate Cancer Screening. Ann Intern Med. 2006;144:441-443. doi: 10.7326/0003-4819-144-6-200603210-00012
Download citation file:
Published: Ann Intern Med. 2006;144(6):441-443.
Prostate cancer screening is controversial, and major professional associations offer differing screening guidelines. The authors address 3 key issues about prostate cancer screening: 1) the prostate-specific antigen (PSA) criteria to recommend a prostate biopsy, 2) the appropriate age to start screening, and 3) the appropriate age to stop screening. The authors argue, on the basis of evidence published since 2000, that data supporting the efficacy of PSA screening are convincing. They recommend screening for risk assessment for average-risk men beginning at age 40 years, screening selected healthy men older than age 70 years, and lowering the PSA threshold for considering biopsy to 2.5 ng/mL for all men.
Learn more about subscription options.
Register Now for a free account.
Hematology/Oncology, Prostate Cancer, Cancer Screening/Prevention, Prevention/Screening.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only